FDA Drug GMP Warning Letters from FY 2012
This article was originally published in The Gold Sheet
The 40 drug GMP warning letters FDA issued in fiscal year 2012 are listed here by type of manufacturing facility, along with a summary of the issues raised.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.